Wyeth

Millennium Pharmaceuticals Limited

William L Trepicchio

Michael E Burczynski

Jennifer Stover

Andrew J Dorner

Natalie C Twine

Stephen J Blakemore

Bin Li

Virginia Fitzpatrick

Fred Immermann

Joseph Boni

Donna K Slonim

Hyunjin Shin

Disclosed herein are markers associated with sensitivity to treatment with therapeutic agents. Methods to identify markers for predicting outcome to treatment with a therapeutic agent are disclosed as well as methods to predict outcome of treatment using markers. Compositions and methods are provided to predict response to NAE inhibition or EGFR inhibition treatment.

Biomarkers and methods to predict response to inhibitors and uses thereof

Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells are modulatable by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for detecting or monitoring drug activities in vivo.

Methods for monitoring drug activities in vivo

Methods, systems and equipment for diagnosing renal cell carcinoma (RCC) and other solid tumors. This invention identifies numerous disease genes that are differentially expressed in the peripheral blood of patients having RCC or other solid tumors relative to disease-free humans. These disease genes can be used as surrogate markers for detecting the presence or absence of RCC or other solid tumors.

Methods for diagnosing RCC and other solid tumors

Growing community of inventors

Andover, MA, United States of America

William L Trepicchio